Page last updated: 2024-11-07

2-propyl-4-pentenoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-propyl-4-pentenoic acid: putative toxic metabolite of valproic acid [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID104896
CHEMBL ID1367
CHEBI ID80634
SCHEMBL ID1000796
MeSH IDM0131140

Synonyms (41)

Synonym
BB 0259440
2-allylpentanoic acid
(+-)-4-en-valproic acid
pentanoic acid, 2-(2-propenyl)-
4-pentenoic acid, 2-propyl-
r,s-4-en-vpa
(+-)-2-n-propyl-4-pentenoic acid
2-allylvaleric acid
brn 1704069
2-propyl-4-pentenoic acid
2-n-propyl-4-pentenoic acid
1575-72-0
4-en-valproic acid
4-ene-vpa
4-en-vpa
CHEMBL1367
chebi:80634 ,
4-en-metabolite
2-propylpent-4-enoic acid
(+/-)-2-propyl-4-pentenoic acid
AKOS006271457
FT-0674112
0-02-00-00452 (beilstein handbook reference)
2gyi36i25w ,
unii-2gyi36i25w
SCHEMBL1000796
valproic acid metabolite .delta.4-valproic acid
(+/-)-2-n-propyl-4-pentenoic acid
.delta.4-valproic acid
UMYDNZXEHYSVFY-UHFFFAOYSA-N
4-ene-valproic acid
LMFA01030982
(+/-)-2-propyl-4-pentenoic acid, analytical standard
J-009424
DTXSID20881257
Q27149680
(+/-)-propyl2-4-pentenoic acid
()-2-propyl-4-pentenoic acid
CS-0084156
HY-124087
( inverted exclamation marka)-2-propyl-4-pentenoic acid

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Our results indicate that all three risk factors clearly increase the metabolic conversion of VPA to 4-en, the most toxic VPA metabolite, and that polytherapy and high VPA serum level result in the inhibited beta-oxidative metabolism of VPA to 2-en."( Associations between risk factors for valproate hepatotoxicity and altered valproate metabolism.
Fukushima, Y; Hirano, T; Ishida, M; Kaneko, S; Koide, N; Kondo, T; Muranaka, H; Otani, K; Yokoyama, M,
)
0.13
" Four of the patients, all on polytherapy, had had short-term adverse effects during chronic VPA treatment, and in them there has been abnormal NH3-values after a test doese of VPA."( Lack of relationship between sodium valproate-induced adverse effects and the plasma concentration of its metabolite 2-propylpenten-4-oic acid.
Arnetoli, G; Bendoni, L; Campostrini, R; Moroni, F; Paganini, M; Zaccara, G; Zappoli, R, 1987
)
0.27
"The aim of this study was to investigate the relationship between hepatotoxicity, levels of glucuronide conjugates of valproic acid (VPA), and the toxic metabolites of VPA (4-ene VPA and 2,4-diene VPA)."( The relationship between glucuronide conjugate levels and hepatotoxicity after oral administration of valproic acid.
Baek, DJ; Chung, BC; Jung, BH; Kim, BJ; Lee, MS; Lee, YJ; Shin, KJ, 2009
)
0.35
"It has been reported that urinary excretion of two metabolites of valproic acid (VPA), 4-ene-valproic acid (4-VPA)and 2,4-diene-valproic acid (2,4-VPA), increased exponentially with the administration of high doses of VPA, and this increased formation of toxic metabolites could be related to VPA hepatotoxicity in humans."( Dose-dependent pharmacokinetics of toxic metabolites is not related to increased toxicity following high-dose valproic acid in rats.
Jung, BH; Kim, BJ; Lee, JH; Lee, MS; Lee, YJ; Oh, JH, 2010
)
0.36
" Although there are many reports of adverse effects of VPA, studies focusing on the concentration-response relationships of VPA and its metabolites in patients with epilepsy are extremely limited."( Simultaneous determination of valproic acid and 2-propyl-4-pentenoic acid for the prediction of clinical adverse effects in Chinese patients with epilepsy.
Chen, SD; Chen, ZJ; Fang, ZY; Huang, M; Li, JL; Shu, WY; Wang, HS; Wang, XD; Zhang, Y; Zhou, JQ; Zhou, LM, 2012
)
0.63

Pharmacokinetics

ExcerptReferenceRelevance
" A time lag pharmacokinetic model was used to describe the plasma profile, including the appearance of a secondary plasma peak, in normal animals receiving the low dose of 4-ene-VPA."( Pharmacokinetics and enterohepatic circulation of 2-n-propyl-4-pentenoic acid in the rat.
Abbott, FS; Orr, JM; Singh, K,
)
0.13
" This investigation was carried out to compare 4-ene VPA and the alpha-fluorinated analogue (alpha-fluoro-4-ene VPA) for their pharmacokinetic and protein binding properties."( A comparative investigation of 2-propyl-4-pentenoic acid (4-ene VPA) and its alpha-fluorinated analogue: phase II metabolism and pharmacokinetics.
Abbott, FS; Tang, W, 1997
)
0.58

Compound-Compound Interactions

ExcerptReferenceRelevance
" It is important to consider the possibility of drug-drug interactions (DDIs)."( Clinical implications of trials investigating drug-drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs.
Critchley, D; Gidal, B; Morrison, G; Patsalos, PN; Szaflarski, JP; VanLandingham, K, 2020
)
0.56

Dosage Studied

ExcerptRelevanceReference
" Urine was collected for one dosage interval (12 h) at steady state for each dose and assayed for 15 VPA metabolites by gas chromatography/mass spectrometry (GCMS)."( Effect of valproate dose on formation of hepatotoxic metabolites.
Acheampong, AA; Anderson, GD; Levy, RH; Wilensky, AJ,
)
0.13
" Blood and urine samples in the studies were collected during a dosing interval at steady state."( Effects of polytherapy with phenytoin, carbamazepine, and stiripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid.
Acheampong, A; Anderson, GD; Baillie, TA; Friel, PN; Guyot, M; Levy, RH; Loiseau, P; Rettenmeier, AW; Tor, J; Wilensky, AJ, 1990
)
0.28
" Male Sprague-Dawley rats (150-180 g, 4 rats per group) were dosed ip with 4-ene VPA (0."( Fluorinated analogues as mechanistic probes in valproic acid hepatotoxicity: hepatic microvesicular steatosis and glutathione status.
Abbott, FS; Borel, AG; Fujimiya, T; Tang, W,
)
0.13
" Bile samples collected from male Sprague-Dawley rats dosed intraperitoneally with 4-ene VPA or its [2H7]-analogue (100 mg kg-1) were injected on to an ODS column interfaced to a LC/MS/MS instrument using electrospray ionization."( Characterization of thiol-conjugated metabolites of 2-propylpent-4-enoic acid (4-ene VPA), a toxic metabolite of valproic acid, by electrospray tandem mass spectrometry.
Abbott, FS; Tang, W, 1996
)
0.29
"
 Results: The correlations between the PLT level and the dosage of VPA (P<0."( Association of valproic acid and 2-propyl-4-pentenoic acid concentrations with adverse reaction in 254 Chinese patients with epilepsy.
Luo, J; Ma, H; Pan, J; Wang, C; Wang, P; Yang, X; Zhu, W, 2019
)
0.8
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
methyl-branched fatty acidAny branched-chain fatty acid containing methyl branches only.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
Valproic Acid Metabolism Pathway1132
Valproic acid pathway022

Bioassays (3)

Assay IDTitleYearJournalArticle
AID243251Inhibitory activity against Glycogen synthase kinase-3 beta, expressed as percent control2004Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22
Examining the correlations between GSK-3 inhibitory properties and anti-convulsant efficacy of valproate and valproate-related compounds.
AID243252Inhibitory activity against Glycogen synthase kinase-3 alpha, expressed as percent control2004Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22
Examining the correlations between GSK-3 inhibitory properties and anti-convulsant efficacy of valproate and valproate-related compounds.
AID250341Anti-convulsant activity in experimental animal model; +++ = more effective2004Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22
Examining the correlations between GSK-3 inhibitory properties and anti-convulsant efficacy of valproate and valproate-related compounds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (36)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (16.67)18.7374
1990's17 (47.22)18.2507
2000's6 (16.67)29.6817
2010's6 (16.67)24.3611
2020's1 (2.78)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.35

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.35 (24.57)
Research Supply Index3.95 (2.92)
Research Growth Index4.67 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.35)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (5.88%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other48 (94.12%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]